Daiichi Sankyo's new cancer drug ADC has been approved for clinical trials in China.

On March 6, the official website of the China National Medical Products Administration Drug Evaluation Center (CDE) announced that the class 1 new drug DS-3939a submitted by Daiichi Sankyo (DSNKY.US) has been approved for clinical trials in the treatment of solid tumors. Public information shows that DS-3939a is an antibody-drug conjugate (ADC) targeting tumor-associated MUC1, currently in phase 1/2 clinical trials globally. According to the CDE website, this is the first time this product has been approved for clinical trials in China. DS-3939a is an ADC targeting TA-MUC1, developed based on Daiichi Sankyo's DXd platform. The product's structure consists of a humanized anti-TA-MUC1 antibody, an enzyme-cleavable tetrapeptide linker, and a DNA topoisomerase I inhibitor with high drug-to-antibody ratio (DAR). The approval of this innovative ADC for clinical trials in China signifies its entry into the clinical research stage in the country.